Prostate Cancer Clinical Trials 2024

What are the top hospitals conducting prostate cancer research?

When it comes to cutting-edge clinical trials in prostate cancer, several top hospitals are making significant strides. Memorial Sloan Kettering Cancer Center in New york takes the lead with seven active trials focused on prostate cancer and an impressive history of 128 completed studies dedicated to this condition. Since recording its first trial back in 1994, this renowned institution has been at the forefront of prostate cancer research. Meanwhile, Dana-Farber Cancer Institute in Boston is also actively involved, currently conducting five clinical trials for prostate cancer and having accomplished a notable total of 89 previous studies since their inaugural trial in 1995.

Moving towards smaller-scale yet equally noteworthy centers, MidLantic Urology located in Bala-Cynwyd pursues four ongoing clinical investigations pertaining to prostate cancer while offering hope through pioneering research which began only a decade ago during2011.Across state lines lies Carolina Urologic Research Center situated at Myrtle Beach where they too undertake four active trials addressing prostrate cancers; their commendable contribution can be traced back eighteen years since initially recording their own trailblazing breakthrough way until2003.Meanwhile, Medical University of South carolina based out Charleston follows suit with four ongoing tests aimed specifically for prostrate ailments uncovering new possibilities by means of forty-seven previously held inquiries after starting fresh experimentation path from1994.

These institutions represent the collective commitment and dedication within the medical community as they strive towards better understanding and treatment options for those affected by prostate cancer. Each study brings us closer to potential breakthroughs that could transform lives worldwide. With these leading hospitals at the forefront, patients can find solace knowing that innovative treatments are being developed and tested every day to fight against one of the most prevalent cancers among men.

Which are the best cities for prostate cancer clinical trials?

When it comes to prostate cancer clinical trials, several cities stand out as leaders in research and development. New york, Los Angeles, Boston, Houston, and Omaha have a significant number of active trials focused on studying different treatments for prostate cancer. These trials investigate various cutting-edge interventions like Apalutamide, Pembrolizumab, Enzalutamide, and more. These cities provide individuals with access to innovative clinical trials that are paving the way for advancements in prostate cancer care and offering hope for improved outcomes.

Which are the top treatments for prostate cancer being explored in clinical trials?

[Prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) clinical trials are investigating several promising treatments to combat this disease. Leading the charge is pembrolizumab, which has shown great potential in four active trials and a total of 34 all-time prostate cancer trials since its introduction in 2014. Another contender, apalutamide, is also making waves with four ongoing trials and an impressive track record of 68 all-time prostate cancer studies since 2013. Not far behind is enzalutamide, currently involved in four active trials and boasting an extensive resume of 163 all-time prostate cancer studies dating back to 2005. Lastly, niraparib joins the ranks with two ongoing trials and a growing list of 13 all-time clinical investigations for prostate cancer since its listing in 2016. These innovative treatments offer hope for patients worldwide as researchers continue their quest towards finding effective solutions against prostate cancer

What are the most recent clinical trials for prostate cancer?

Exciting advancements in prostate cancer research have led to the development of several recent clinical trials. Among them, a Phase 1 trial is exploring dose optimization for prostate cancer treatment, aiming to refine and improve therapeutic strategies. In another Phase 2 trial, the efficacy and safety of Relugolix are being evaluated as a potential treatment option for prostate cancer. Additionally, an innovative Phase 1 trial is investigating the use of NPX267 therapy specifically tailored for prostate cancer patients. Lastly, a combined Phase 1/Phase 2 study explores the effectiveness of 67Cu-SAR-BBN in targeting prostate cancer cells. These groundbreaking trials offer hope for improved outcomes and more personalized approaches to treating this challenging disease.

What prostate cancer clinical trials were recently completed?

Several significant clinical trials for prostate cancer have recently been completed, demonstrating the continuous efforts to advance treatment options. Noteworthy among these is a trial sponsored by Clarity Pharmaceuticals Ltd., which concluded in April 2022, investigating the potential of 64Cu-SAR-bisPSMA. Similarly, Surface Oncology's study on SRF617 reached completion in January 2022, while a trial led by Ryan Kohlbrenner, MD focused on Catheterization was finalized in October 2021. These recent developments contribute to our understanding and progress towards more effective management of prostate cancer.